CNBC Stock Blog
- How Stock Investors Can Play Holiday Travel
- 3 Growth Opportunities in Tech: Analyst
- Prep Your Portfolio for Next Week: Stock Pickers
- Global Growth Good for Portfolio: Stock Picker
- Expect Tech Sector to Rise in Q4: Strategist
- Expect a 5-10% Market Pullback: Stock Picker
- 3 Stock Picks for This Volatile Environment: Portfolio Manager
- 3 Financial Stocks May Lead Final Rally: Market Researcher
- Gold's 'Money' Value is $4,000 to $11,000: Market Strategist
- Commercial Real Estate Bottom Near: Market Pro
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Late Payments on Credit Cards Drop in Third Quarter
- Smallest US Businesses Borrowing Again: PayNet
- US Job Losses to Bottom out Next Quarter: NABE
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- Wall Street Finds Profits by Reducing Mortgages
- Warren Buffett, Bill Gates 'Walk & Talk' At Columbia
- Microsoft, News Corp Weigh Online News Pact
- 10 Tips to Get Out of Debt
RSS FEED
Text Size 
CNBC News Associate
Markets opened higher on Wednesday, helped by a positive jobs data. Where should investors be looking right now? Bernard Lirola, fund manager of the Needham Aggressive Growth Fund, shared his favorite stock picks.
Lirola's Recommendations:
Trimble Navigation [TRMB
Loading...
()
]—“They create efficiencies for businesses,” Lirola told CNBC.
“They do it through a combination of equipment and software…It is an efficiency driven company…I’m hoping the stock will gain 50 percent in 2 years.”
Express Scripts [ESRX
Loading...
()
]—“They try to drive the cost of drugs down for corporations and also for government,” he said of the firm.
“We see them doubling their earnings to about $7 a share in 3 years, so we’re very happy to pay just 15 times next year earnings for that growth.”
Gilead Sciences [GILD
Loading...
()
]—“They are the leading viral drug solution company in the world—75 percent of HIV patients in the U.S. are treated with their drugs and only 65 percent in Europe, so there’s growth opportunity there,” he said.
“But [Gilead] is also expanding their research to other lines of viral issues, so I see them being taken over by pharmaceutical companies because anti-viral research is very important. They trade at $43, I hope that they’d be taken out in 2 to 3 years at $75 a share.”
______________________________
Other Market Opinions:
- Stock Picker: Buffett Will Target These Industries Next
- 4 High Dividend Yielding Stocks: Portfolio Manager
- Where to Invest Now: Two Strategists' Views
______________________________
CNBC Data Pages:
______________________________
CNBC Slideshows:
______________________________
______________________________
Disclosures:
No immediate information was available for Lirola or his firm.
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes